Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein

Key facts

Sponsor

Jiangsu Gensciences lnc.

Principal Investigator

Renchi Yang

Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College.

Intervention

FRSW117(drug)

Enrollment

120 target

Eligibility

12-65 years · MALE

Timeline

2023 – 2026

Study locations (28)

• Beijing tongren hospital,CMU, Beijing, China
• XiangYa Hospital CentralSouth University, Changsha, China
• The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
• Fujian Medical University Union Hospital, Fuzhou, China
• Nanfang Hospital of Southern Medical University, Guangzhou, China
• The First Affiliated Hospital，Zhejiang University School of Medicine, Hangzhou, China
• Anhui Provincial Hospital, Hefei, China
• Jinan central hospital, Jinan, China
• The First Affiliated Hospital of Shandong First Medical University, Jinan, China
• The Second Affiliated Hospital of Kunming Medical University, Kunming, China
• The First Hospital of Lanzhou University, Lanzhou, China
• Jiangxi Provincial People's Hospital, Nanchang, China
• Nanjing Drum Tower Hospital, Nanjing, China
• Affiliated Hospital of Nantong University, Nantong, China
• The Affiliated Hospital of Qingdao University, Qingdao, China
• +13 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Severe hemophilia A

Additional recruiting or active studies for the same condition.

• ENROLLING BY INVITATIONNANCT06816953
  Cartilage Biomarkers and HEAD-US Score in Severe Hemophilia A Patients Receiving FVIII Prophylaxis
  Chulalongkorn University
• ACTIVE NOT RECRUITINGPHASE3NCT06224907
  Phase 3 Study for Efficacy and Safety Outcomes Data in Japanese Patients With Severe Hemophilia A
  BioMarin Pharmaceutical
• RECRUITINGNCT05981274
  A Study on the Bone-health Effectiveness of Applying Recombinant Factor VIII Fc (rFVIIIFc) to Patients With Hemophilia A (Prototype A)
  Tri-Service General Hospital
• ENROLLING BY INVITATIONNCT05768386
  A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401)
  BioMarin Pharmaceutical
• RECRUITINGPHASE4NCT04690322
  POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies
  University of Texas Southwestern Medical Center

See all trials for Severe hemophilia A →